Sanofi Stops Supplying Hydroxychloroquine to COVID-19 Patients in Clinical Trials The malaria drug is quickly falling out of favor with the medical community as a potential treatment for the disease. Eric Volkman (TMFVolkman) May 29, 2020 at 11:00PM Author Bio On the back of mounting concerns about hydroxychloroquine's safety, global pharmaceutical major Sanofi (NASDAQ:SNY) has quit providing it to COVID-19 patients enrolled in its clinical trials for the drug. It has also put a temporary halt on recruiting new subjects for the research. Hydroxychloroquine, originally designed to treat malaria, was formerly considered a potential treatment for COVID-19, the disease that can result from the SARS-CoV-2 coronavirus. It had some high-level support, most notably from President Donald Trump, who at one point claimed he was regularly taking it. IMAGE SOURCE: GETTY IMAGES. The pharmaceutical giant's decision follows the World Health Organization's (WHO's) stoppage of its own clinical trials on hydroxychloroquine and the subsequent banning of the drug's use by several European countries. The source of its concern is a recent paper published in U.K. medical journal The Lancet, indicating increased death rates from taking the medication. That paper, which is based on an analysis of medical records, is not the only research that has found the drug might not be appropriate for COVID-19 patients. Last month, a similar analysis of 368 U.S. veterans also indicated elevated death rates in patients receiving the treatment. Two randomized, controlled clinical trials were being conducted by Sanofi to test hydroxychloroquine's efficacy in fighting COVID-19. One was a multinational study involving 210 patients presenting an early stage of the disease. These individuals had not been hospitalized. The other, larger one involved roughly 300 people suffering from moderate to severe forms of the disease who had been hospitalized; this was limited to Europe. On Friday, shares of Sanofi inched up by 0.9%, roughly in line with the performance of the wider stock market on the day. 10 stocks we like better than Sanofi When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Sanofi wasn't one of them! That's right -- they think these 10 stocks are even better buys. See the 10 stocks *Stock Advisor returns as of April 16, 2020 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Sanofi makes Plaquinol you igit. They are also making a vaccine, they can sell both. Do you think they would end research into something they already own for no reason? Reformulatet as Plaquinol-Z with zinc/zombie apocalypse and charge even more. Not enough profit in over 7 billion customers between this and the vaccine they are also developing?
Even the Lancet seems to have been infected by TDS. Bunch of idiots. Hydroxychloroquine Study Corrected After More Than 100 Scientists Question Findings https://link.theepochtimes.com/mkt_...100-scientists-question-findings_3371001.html Download The Epoch Times app to see our exclusive CCP virus coverage and daily updates:https://subscribe.theepochtimes.com/p/?page=mobile
Hey hey genius, care to post a working link or just the part where it says what the correction was? Seemed they included one Asian hospital in the Oz dataset which had no effect on the study collisions. Was there more? Nobody installing the Pseudoscience Times app here. The update was trivial. As you are an uneducated fella, we will explain, papers get published, then go to peer review. Sometimes if very interesting they get wider comments prior to this and these form a part of the review. Nothing strange, nothing discredited yet. "The appendix has also been corrected. An incorrect appendix table S3 was included, originally derived from a propensity score matched and weighted table developed during a preliminary analysis. The unadjusted raw summary data are now included.” The Lancet added that there “have been no changes to the findings of the paper,” and that the corrections have been made to the online version and will also be made to the printed version."
The first link works, but then I guess is too much for you to figure out. Here it is. It's all cooked up shit. https://theepochtimes.com/mkt_app/hydroxychloroquine-study-corrected-after-more-than-100-scientists-question-findings_3371001.html?v=ul
You dumb cunt, how many times were your dropped on the head.. You are adding an app link. Retard. I'll do it for you, cretin. https://www.theepochtimes.com/hydro...scientists-question-findings_3371001.html/amp
Maybe but it stalls completely on my up to date chrome. It does not say that. You are just an igit. Dataset errors happen, this is the purpose of review and comment. It may be that in peer review other issues are addressed, but for now it's just like any other paper.
You should get your head out of the MSM's ass if you really want to know what is happening in the world. The Epoch Times is a good source for information, specially CCP. Here it is: Hydroxychloroquine Study Corrected After More Than 100 Scientists Question Findings May 31, 2020 15:14, Last Updated: May 31, 2020 15:36 By Katabella Roberts Medical journal The Lancet on May 29 issued a correction to a recent study which found that antimalarial drugs Hydroxychloroquine and chloroquine were linked with an increased risk of mortality in hospitals, and an increased frequency of irregular heart rhythms. The study, titled, “Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis,” and published on May 22, included records of 96,032 patients from 671 hospitals in six continents. The patients were hospitalized between Dec. 20, 2019, and April 14, 2020. Patients receiving the anti-malarials were put in four different groups: chloroquine alone, chloroquine with a macrolide, hydroxychloroquine alone, or hydroxychloroquine with a macrolide. Patients who received none of the treatments formed a control group. Researchers found the 14,888 patients in the treatment group suffered higher mortality when compared to the control group of over 80,000. Protect yourself against fake news. Get real news directly to your phone. Download The Epoch Times app here. “We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19,” the researchers wrote. The study led the World Health Organization to temporarily suspend the trial of hydroxychloroquine on COVID-19 patients, and to the UK regulatory body, MHRA, requesting the temporary pause of recruitment into all hydroxychloroquine trials in the UK. France also changed its national recommendation of the drug in COVID-19 treatments and halted all trials. A pharmacy tech pours out pills of hydroxychloroquine at Rock Canyon Pharmacy in Provo, Utah, on May 20, 2020. (George Frey/AFP via Getty Images) However, more than a hundred scientists and medical professionals raised questions about integrity of data analyzed in the study and subsequently wrote an open letter to its authors and the editor of The Lancet, listing 10 major concerns. These included the fact that there was “no ethics review,” and “unusually small reported variances in baseline variables, interventions and outcomes,” as well as “no mention of the countries or hospitals that contributed to the data source and no acknowledgments to their contributions.” A request to the authors for information on the contributing centers was denied, the letter said. Among the scientists other concerns were that the average daily doses of hydroxychloroquine were higher than the FDA-recommended amounts and that data reportedly from Australian patients did not seem to match data from the Australian government. “Too many cases for just five hospitals, more in hospital deaths than had occurred in the entire country during the study period,” they wrote, noting that Surgisphere, a healthcare data analytics company, has since stated this was an error of classification of one hospital from Asia. “This indicates the need for further error checking throughout the data base,” they wrote. The scientists also said the authors “have not adhered to standard practices in the machine learning and statistics community. They have not released their code or data.” “Data from Africa indicate that nearly 25% of all COVID-19 cases and 40% of all deaths in the continent occurred in Surgisphere-associated hospitals which had sophisticated electronic patient data recording, and patient monitoring able to detect and record ‘nonsustained [at least 6 secs] or sustained ventricular tachycardia or ventricular fibrillation.’ Both the numbers of cases and deaths, and the detailed data collection, seem unlikely.” A pharmacist shows a bottle of the drug hydroxychloroquine in Oakland, Calif., on April 6, 2020. (Ben Margot/AP Photo) The Lancet’s study was informed by data from Surgisphere of which Sapan Desai, the president and Chief Executive Officer, is listed as one of the four authors. “We discovered that a hospital that joined the Surgisphere registry on April 1, 2020 (in between our quarterly audit periods) self-designated as belonging to the Australasia continental designation. In reviewing the data from each of the hospitals in the registry, we noted that this hospital should have more appropriately been assigned to the Asian continental designation,” Surgisphere said in a statement. “This hospital was properly reclassified in our database. The findings of the paper are unaffected by this update,” the company said. In the correction issued on Friday, The Lancet also mentioned the same hospital. “The appendix has also been corrected. An incorrect appendix table S3 was included, originally derived from a propensity score matched and weighted table developed during a preliminary analysis. The unadjusted raw summary data are now included.” The Lancet added that there “have been no changes to the findings of the paper,” and that the corrections have been made to the online version and will also be made to the printed version. In response to the correction issued on May 29, James Watson, a Thailand-based statistician with the University of Oxford’s Centre for Tropical Medicine and Global Health, who led the drafting of the letter, told BuzzFeed News that the authors of the study had failed to address the other nine points referred to in the letter.